Eisai Co Ltd

Type: Company

Name: Eisai Co Ltd (Eisai Co. Ltd)

Nationality: Japan

Web Address: http://www.eisai.co.jp/

Fact Sheet: Fact Sheet for Eisai Co Ltd

First reported 6 hours ago - Updated 6 hours ago - 1 reports

Research and Markets Adds Report: Global Alzheimer's Drugs Market 2012-2016

Research and Markets has announced the addition of the "Global Alzheimer's Drugs Market 2012-2016" report to its offerings. In a release, Research and Markets noted that report highlights include:One of the key factors contributing to this market growth ... [Published Individual.com - 6 hours ago]

Entities: Alzheimer's Disease, Drugs, Market

First reported Jun 18 2013 - Updated 18 hours ago - 2 reports

Eisai to beef up Hatfield pharma pack plant

Eisai Manufacturing, the company?s UK manufacturing subsidiary operates the Hatfield plant in Hertfordshire, which serves as a global supply centre for new products such as antiepileptic agent Fycompa.The plant also functions as a production and packaging ... [Published PackagingNews.co.uk - 18 hours ago]

Entities: Eisai Co Ltd, Manufacturing, Fycompa, anticonvulsant, United Kingdom

First reported Jun 17 2013 - Updated Jun 18 2013 - 2 reports

Eisai Co Ltd

Eisai to expand pharma packaging plant in UK

Japanese pharmaceutical company Eisai is all set to invest £8m at its Hatfield, Hertfordshire production plant in the UK to create an additional packaging facility. ... [Published Packaging Business Review - Jun 18 2013]

Entities: Eisai Co Ltd, United Kingdom

First reported Jun 18 2013 - Updated Jun 18 2013 - 2 reports

Eisai To Expand U.K. Production, Packaging Plant In Time For New Drugs

Eisai plans to expand its U.K. global packaging plant in time for several new drugs it plans to launch, including Fycompa (perampanel) for treating epilepsy. ... [Published The Rose Sheet - Jun 18 2013]

Entities: Eisai Co Ltd, Drugs, Perampanel, Fycompa

First reported Jun 17 2013 - Updated Jun 17 2013 - 5 reports

Eisai Expands UK Site with New Facility

Japanese Pharmaceutical Company HATFIELD, England, June 17, 2013 /PRNewswire/ -- New, high tech, global packaging facility for Eisai's investigational thyroid cancer treatment Eisai... ... [Published Drugs.com - Jun 17 2013]

Entities: Eisai Co Ltd, United Kingdom, investigational

First reported Jun 17 2013 - Updated Jun 17 2013 - 2 reports

Cheung Kong Holdings Limited

ASIA MARKETS: Japan Stocks Jump, Lead Asia Ahead Of Fed Meet

HONG KONG (MarketWatch) -- Most Asian markets extended gains on Monday, with Japanese stocks staging a strong rebound from a weak start as many major exporters climbed on the yen's retreat.Stocks in multiple regional markets overcame choppy early trading ... [Published 4 Traders - Jun 17 2013]

Entities: China Overseas Land & Investment Ltd, Cheung Kong Holdings Limited, Eisai Co Ltd, Japan Tobacco Inc

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

Japan Tobacco Inc

Nikkei closes up 346 pts to 13033

The Nikkei 225 Stock Average closed up 346.6 pts, or 2.73%, to 13033.12.Japan Tobacco surged 5%. Takeda Pharmaceutical and Eisai advanced 3% and 5%.AAStocks Financial NewsWeb Site: www.aastocks.comNews Provided by AASTOCKS.com ... [Published Aastocks.com - Jun 17 2013]

Entities: Nikkei Index, Eisai Co Ltd, Japan Tobacco Inc

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

AbbVie Eisai Humira Pre-Filled Syringe Approved in Japan for Ulcerative Colitis

AbbVie and Eisai Announce HUMIRA Pre-filled Syringe 40 mg / 0.8 mL, a Fully Human Monoclonal Anti-TNF-? Antibody Formulation, Has Received Approval for the Treatment of Moderate to Severe Ulcerative Colitis (UC) in Japan HUMIRA Becomes the First and Only ... [Published Big News Network - Jun 14 2013]

Entities: Eisai Co Ltd, AbbVie, HUMIRA, Ulcerative Colitis

First reported Jun 13 2013 - Updated Jun 14 2013 - 2 reports

Arena Pharmaceuticals: A Trading Vehicle, At Best

Contrary to the expectations and hopes of many, prevailing circumstances strongly suggest that speculators hanging their hats on a buyout of Arena Pharmaceuticals (NASDAQ: ARNA) will be sorely disappointed. Moreover, a fundamental assessment of the small ... [Published Seeking Alpha - Jun 14 2013]

Entities: Arena Pharmaceuticals Inc, Eisai Co Ltd, Buyout

First reported Jun 13 2013 - Updated Jun 14 2013 - 4 reports

Epizyme Inc earns USD6m milestone payment upon enrollment of first patient in Phase 1/2 clinical trial of EPZ-6438

Biopharmaceutical company Epizyme Inc (EPZM) announced on Thursday the admission of the first patient in a Phase 1/2 clinical trial of EPZ-6438 (E7438) for the treatment of non-Hodgkin lymphoma patients who have a cancer-causing (oncogenic) point mutation ... [Published Individual.com - Jun 14 2013]

Entities: Epizyme Inc, Phase I, Clinical trials

First reported Jun 13 2013 - Updated Jun 13 2013 - 2 reports

Eisai Announces Sponsorship of CURE Benefit to Support Epilepsy Research and Awareness

CURE is a nonprofit organization focused on finding a cure for epilepsy by raising research funds and increasing epilepsy awareness. The organization was founded by Susan Axelrod"CURE and Eisai have a common objective â to improve the lives of those affected ... [Published Street Insider - Jun 13 2013]

Entities: Epilepsy, Eisai Co Ltd, Susan Axelrod, Eisai Inc.

First reported Jun 12 2013 - Updated Jun 13 2013 - 2 reports

Why The Newest Short Thesis On Arena Is Dead Wrong And Should Be Ignored

Home » Blogs » Arena Pharmaceuticals (ARNA) has finally launched its long awaited novel weight loss drug, Belviq, with the help of pharmaceutical company Eisai, and the excitement about the immense potential for Arena shareholders and tension between ... [Published BioPortfolio - Jun 13 2013]

Entities: Qsymia, Eisai Co Ltd, Weight Loss, Jack Lief

Quotes

"The suggestion that obesity is not a disease but rather a consequence of a chosen lifestyle exemplified by overeating and/or inactivity is equivalent to suggesting that lung cancer is not a disease because it was brought about by individual choice to smoke cigarettes" the resolution said

American Medical Association recognises obesity as a disease [Published NDTV - 3 hours ago]

With the AMA news the jobs of those 50 reps just got a lot easier. A rep can now say, "The AMA has classified obesity as a disease. As you know, obesity adds to many other health issues that carry great costs to the healthcare system. We offer a treatment for obesity that allows patients to lose critical pounds and thereby save the healthcare system money. With obesity classified as a disease by the AMA we feel that it is important that your company cover this treatment." Doctors will also be empowered...

American Medical Association Decision Can Boost Arena, Vivus, And Orexigen [Published Seeking Alpha - 6 hours ago]

"More than just weight loss alone may explain the significant improvement in glycemic control associated with lorcaserin" Aronne said

Blood Sugar Control Improved By Weight Loss Drug Plus Diet And Exercise [Published Medical News Today - Jun 18 2013]

More From BioPortfolio on "Eisai To Expand U K Production, Packaging Plant In Time For New Drugs"

Eisai To Expand U.K. Production, Packaging Plant In Time For New Drugs [Published BioPortfolio - Jun 18 2013]

More Content

sort by: Date \| Relevance
American Medical Association recognises obesity... [Published NDTV - 3 hours ago]
Research and Markets Adds Report: Global Alzhei... [Published Individual.com - 6 hours ago]
American Medical Association Decision Can Boost... [Published Seeking Alpha - 6 hours ago]
Eisai to beef up Hatfield pharma pack plant [Published PackagingNews.co.uk - 18 hours ago]
Eisai to expand pharma packaging plant in UK [Published Packaging Business Review - Jun 18 2013]
Blood Sugar Control Improved By Weight Loss Dru... [Published Medical News Today - Jun 18 2013]
Eisai To Expand U.K. Production, Packaging Plan... [Published The Rose Sheet - Jun 18 2013]
Eisai To Expand U.K. Production, Packaging Plan... [Published BioPortfolio - Jun 18 2013]
Eisai invests in UK Hatfield production plant t... [Published PBR - News - Jun 18 2013]
Another Alzheimer’s drug candidate suffers setback [Published Terrapinn - Jun 17 2013]
Eisai Expands UK Site with New Facility [Published Drugs.com - Jun 17 2013]
Weight Loss Drug Added to Diet and Exercise Imp... [Published Newswise - Jun 17 2013]
Eisai to expand global packaging facility in UK [Published Manufacturing Chemist - Jun 17 2013]
Eisai Expands UK Site to Package Anticancer and... [Published Pharma-Mag - Jun 17 2013]
UPDATE 2: Japan stocks jump, lead Asia ahead of... [Published TD Ameritrade - Jun 17 2013]
ASIA MARKETS: Japan Stocks Jump, Lead Asia Ahea... [Published 4 Traders - Jun 17 2013]
EISAI TO MAKE NEW INVESTMENT IN EXPANSION OF GL... [Published Noodls - Jun 17 2013]
Nikkei closes up 346 pts to 13033 [Published Aastocks.com - Jun 17 2013]
ASIA MARKETS: Japan Stocks Rebound As Asia Awai... [Published EuroInvestor - Jun 17 2013]
Japanese Pharmaceutical Company Eisai Expands U... [Published ADVFN UK - Jun 17 2013]
Japanese Pharmaceutical Company Eisai Expands U... [Published FinanzNachrichten.de - Jun 17 2013]
ASIA MARKETS: Japan Stocks Rebound As Asia Awai... [Published 4 Traders - Jun 17 2013]
Japan's Nikkei rises, spurred by defensive buying, [Published CNBC - Jun 17 2013]
COQ2 Gene Variant Tied to Brain Disorder (CME/CE) [Published MedPage Today - Jun 16 2013]
Lilly Terminates Alzheimer's Drug Trial, Citing... [Published MediLexicon - Jun 16 2013]
Lilly Halts Phase II Study of Alzheimer's Candi... [Published Genetic Engineering News - Jun 14 2013]
"Eisai Co., Ltd. - SWOT, Strategy and Corporate... [Published PR inside - Jun 14 2013]
AbbVie Eisai Humira Pre-Filled Syringe Approved... [Published Big News Network - Jun 14 2013]
Arena's Belviq Does Not Fare Well With Consumer... [Published BioPortfolio - Jun 14 2013]
Arena Pharmaceuticals: A Trading Vehicle, At Best [Published Seeking Alpha - Jun 14 2013]

sort by: Date \| Relevance
Eisai invests in UK Hatfield production plant t... [Published PBR - News - Jun 18 2013] Eisai, a Japanese pharmaceutical company, has decided to invest a total sum of approximately £8m in the expansion of its Hatfield manufacturing unit in UK. ...
Eisai Expands UK Site to Package Anticancer and... [Published Pharma-Mag - Jun 17 2013] Eisai is investing over £8 million into the construction of a new packaging facility at its existing EMEA (Europe, Middle East, Africa, Russia and Oceania) Knowledge Centre at Hatfield, UK. The new facility, due to for completion by mid-2014, will add ...
4 Healthcare Stock Stories For Thursday Inspection [Published Wall St. Cheat Sheet - Jun 11 2013] Forest Laboratories ( NYSE:FRX ): Closing price $39.85Forest reported Tuesday that, through an agreement with Carl C. Icahn and affiliated entities, the board has named Vincent J. Intrieri as a new independent member. Fulfilling a part of the arrangement, ...
4 Healthcare Stock Stories For Thursday Inspection [Published Wall St. Cheat Sheet - Jun 11 2013] Forest Laboratories ( NYSE:FRX ): Closing price $39.85 Forest reported Tuesday that, through an agreement with Carl C. Icahn and affiliated entities, the board has named Vincent J. Intrieri as a new independent member. Fulfilling a part of the arrangement, ...
Eisai to market and distribute Belviq weight ma... [Published PBR - News - Jun 10 2013] Eisai has announced the availability of Belviq (lorcaserin HCl) CIV tablets in the US, which is designed for chronic weight management in adults who are overweight with a comorbidity or obesity. ...